Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul;205(1):373-377.
doi: 10.1111/bjh.19524. Epub 2024 May 12.

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia

Affiliations
Case Reports

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia

Marie Emilie Dourthe et al. Br J Haematol. 2024 Jul.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
    1. Laetsch TW, Maude SL, Rives S, Hiramatsu H,Bittencourt H,Bader P, et al. Three‐year update of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664–1169.
    1. Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated analysis of the efficacy and safety of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):895.
    1. Schultz LM, Baggott C, Prabhu S, Pacenta H, Phillips CL, Rossoff J, et al. Disease burden impacts outcomes in pediatric and young adult B‐cell acute lymphoblastic leukemia after commercial Tisagenlecleucel: results from the pediatric real world CAR consortium (PRWCC). Blood. 2020;136(Supplement 1):14–15.
    1. Dourthe M‐E, Rabian F, Yakouben K, Chevillon F, Cabannes‐Hamy A, Méchinaud F, et al. Determinants of CD19‐positive vs CD19‐negative relapse after tisagenlecleucel for B‐cell acute lymphoblastic leukemia. Leukemia. 2021;35(12):3383–3393.

MeSH terms

LinkOut - more resources